Jane E. Ambler

Dr. Ambler has served as our Vice President of Clinical Microbiology since February 2020. Dr. Ambler has over 25 years of experience working in antibacterial drug development in the pharmaceutical industry and a hospital antibiotic research laboratory. Prior to joining ContraFect, Dr. Ambler served as Vice President of Clinical Microbiology at Wockhardt, responsible for clinical microbiology aspects of Phase 2 and 3 clinical trials (including nafithromycin, cefepime-zidebactam, cefepime-tazobactam and levonadifloxacin) and the coordinated development of commercial antibacterial susceptibility test (AST) systems with AST device manufacturers. Previously, Dr. Ambler served in various roles of increasing responsibility at SmithKline Beecham (UK), Bayer (UK, Germany and US), AstraZeneca and Cubist (acquired by Merck) in the US. Dr. Ambler has contributed to numerous successful new drug applications (NDAs), marketing authorization applications (MAAs) and supplemental NDAs, including for gemifloxacin, moxifloxacin, ciprofloxacin, ceftaroline, ceftazidime-avibactam and levonadifloxacin. In addition, Dr. Ambler has extensive experience contributing to global regulatory strategy and product lifecycle management, participating in regulatory agency meetings around the world (FDA, Health Canada, EMA, CFDA, TGA, New Zealand, and COFEPRIS), and leading interactions with antibacterial susceptibility standards organizations (CLSI and EUCAST). Dr. Ambler is a member of the core faculty of the Institut Pasteur’s Interdisciplinary Course on Antibiotics and Resistance (ICARe) and is an active Clinical and Laboratory Standards Institute (CLSI) member and volunteer working on various Working Groups and ESCMID (European Society for Clinical Microbiology and Infectious Diseases) member.

Dr. Ambler received her Ph.D. from The School of Pharmacy, University College London (formerly the University of London), UK. Following her research collaborations with the North Middlesex Hospital, London, Dr. Ambler subsequently managed the Antibiotic Research Laboratory at the hospital for five years.